- Bullseye Trades
- Posts
- Santa Rally? ONCY’s Taking Off—Don’t Miss Out! 🚀
Santa Rally? ONCY’s Taking Off—Don’t Miss Out! 🚀
Hot press releases, big partnerships, and breakout potential.
Sponsored by Market IQ Media Group*
TODAY’S TOP ALERT!
Oncolytics Biotech (Nasdaq: ONCY)
Merry Christmas Eve, folks!
May your home be filled with warmth, joy, and laughter tonight.
As I hope you know, it’s a shortened trading day, with the markets closing at 1 pm ET this afternoon.
Stocks opened up this morning, with the S&P 500 up about 0.3% and the Nasdaq up 0.5% as of this writing…
Investors are feeling one last spurt of optimism before Santa takes to the skies. 📈🎅🏻📈
I won’t be doing too much trading today, but one stock I’m keeping a close eye on 👀 is my “tactical trade” idea from yesterday: Oncolytics Biotech Inc. (ONCY).
👉 ONCY is TODAY’S #1 ALERT 👈
The stock had a picture-perfect uptrend yesterday, and did well again in after-hours and pre-market trading…
It’s off to the races after the opening bell 🏇🔔 and I think the next few hours could be very exciting.
In case you missed my update yesterday afternoon, ONCY put out a press release yesterday that reads almost like a shareholder letter…
I recommend reading it in its entirety for a helpful summary of where the company stands, but in brief, the company touted its lead candidate’s “robust efficacy results” and upcoming trials, a collaboration with pharma heavyweight Roche, and a January presentation at the Biotech Showcase in San Francisco…
There’s a lot of interest among oncology experts in the company’s innovative candidate, pelareorep, a reovirus that the company says has “the power to awaken the immune system and unlock its antitumor potential.”
Definitely check out this newly released corporate presentation as well as the company’s very accessible and informative website if you haven’t had a chance.
And keep watching ONCY closely as the shortened trading day unfolds!
In the meantime, Merry Christmas to all who celebrate, from my family to yours. 🎄
To Your Success,
Jeff Bishop
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”
Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received thirty five thousand dollars (cash) from Market IQ Media Group for advertising Oncolytics Biotech Inc for a three-day marketing program starting on December 23, 2024
Previously, we received twenty thousand dollars by ach bank transfer by Axe Communications for advertising Oncolytics Biotech Inc for a one-day advertising program. This was paid by someone else not connected to Oncolytics Biotech Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.
Now, diving right into Oncolytics Biotech Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear,
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.
So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.